MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Pheochromocytoma

  • Home
  • Pheochromocytoma
Octreotide in the Management of Catecholamine-Secreting Pheochromocytomas and Paragangliomas: A Promising Adjunctive Therapy
Posted inDiabetes & Endocrinology news

Octreotide in the Management of Catecholamine-Secreting Pheochromocytomas and Paragangliomas: A Promising Adjunctive Therapy

Posted by By MedXY 08/22/2026
Octreotide shows potential as an effective adjunctive therapy in catecholamine-secreting pheochromocytomas and paragangliomas, improving biochemical, hemodynamic, and metabolic parameters and supporting perioperative management.
Read More
Safety of Biopsy in Pheochromocytoma and Paraganglioma: What a Global Study Found
Posted innews Oncology Pathology & Lab Medicine/Bệnh học

Safety of Biopsy in Pheochromocytoma and Paraganglioma: What a Global Study Found

Posted by By MedXY 05/15/2026
This international study found that biopsy of pheochromocytoma and paraganglioma had low mortality and low serious complication rates, suggesting biopsy may be reasonable in carefully selected patients with expert management.
Read More
Most Bilateral Adrenal Lesions Are Benign and Concordant, but Asynchronous Presentation Signals Higher Malignancy Risk
Posted inDiabetes & Endocrinology news Oncology

Most Bilateral Adrenal Lesions Are Benign and Concordant, but Asynchronous Presentation Signals Higher Malignancy Risk

Posted by By MedXY 05/13/2026
A large retrospective cohort shows that bilateral adrenal masses are usually benign and concordant, but asynchronous or discordant lesions identify a clinically important subgroup enriched for malignancy and pheochromocytoma.
Read More
Preemptive Magnesium Sulfate Infusion Significantly Stabilizes Hemodynamics During Pheochromocytoma Resection
Posted inAnesthesiology Diabetes & Endocrinology news

Preemptive Magnesium Sulfate Infusion Significantly Stabilizes Hemodynamics During Pheochromocytoma Resection

Posted by By MedXY 01/19/2026
A randomized, double-blind trial confirms that preemptive magnesium sulfate reduces intraoperative hemodynamic instability by nearly 50% in patients undergoing pheochromocytoma and paraganglioma resection, providing a safe and effective adjunct to standard anesthetic protocols.
Read More
Targeting Tumor Hypoxia Pathways: Belzutifan’s Promise in Advanced Paraganglioma and Pheochromocytoma Treatment
Posted inDiabetes & Endocrinology Oncology

Targeting Tumor Hypoxia Pathways: Belzutifan’s Promise in Advanced Paraganglioma and Pheochromocytoma Treatment

Posted by By MedXY 10/25/2025
This article reviews a phase 2 trial of belzutifan, a HIF-2α inhibitor, demonstrating durable antitumor activity and manageable safety in advanced pheochromocytoma and paraganglioma, highlighting its potential as a targeted therapy.
Read More
  • DOACs versus Warfarin for Cerebral Venous Thrombosis: Noninferiority Confirmed in Large-Scale Chinese Registry Study
  • Focal Congenital Hyperinsulinism: Insights Into Spontaneous Glycemic Improvement Before Surgical Intervention
  • Return to Competition and Career Sustainability After Primary ACL Reconstruction in Football: Insights from Nationwide and Long-Term Studies
  • Predicting Walking Ability in Nontraumatic Spinal Cord Injury Using Machine Learning: A Novel Temporal Validation Study
  • Decoding Fluoride Discourse on X During the 2024 US Presidential Election: Implications for Public Health Communication
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top